ENDRA Life Sciences (NDRA) Share-based Compensation (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Share-based Compensation for 11 consecutive years, with $3.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 7538.57% year-over-year to $3.0 million in Q2 2026; TTM through Jun 2026 was $3.0 million, a 454.29% increase from a year earlier, with the FY2025 full-year figure at $329409.0, down 42.4% from the prior year.
• Share-based Compensation was $3.0 million for Q2 2026 at ENDRA Life Sciences, roughly flat from $3.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $8.0 million in Q3 2022 and troughed at $279.0 in Q3 2024.
• A 5-year average of $1.9 million and a median of $470868.5 in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 99.96% in 2024 and surged 37450.18% in 2025, its largest moves.
• Over 5 years, Share-based Compensation stood at $290769.0 in 2022, then decreased by 13.83% to $250557.0 in 2023, then sank by 58.22% to $104684.0 in 2024, then plunged by 98.06% to $2028.0 in 2025, then surged by 148791.77% to $3.0 million in 2026.
• The last three Share-based Compensation figures came in at $3.0 million (Q2 2026), $3.0 million (Q1 2026), and $2028.0 (Q4 2025), per Business Quant data.